Clinical trials: Inflammatory
Colitis, Ulcerative
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- PURSUIT 2 (NCT03596645)
- Testing
- Golimumab, Infliximab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 84 people
- Sponsor
- Janssen Research & Development, LLC
Septic Shock
Lipopolysaccharide Adsorption At Septic Shock
Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\or excess of cytokines improve…
- Trial name
- LASSO (NCT04827407)
- Testing
- Efferon LPS hemoperfusion
- Where
- 4 sites in Russia
- Volunteers
- 58 people
- Sponsor
- Efferon JSC
Ulcerative Colitis
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)
This study was designed to evaluate how the body processes and removes mirikizumab. The study also evaluated safety and disease response in pediatric participants with UC taking mirikizumab.
- Trial name
- SHINE-1 (NCT04004611)
- Testing
- Mirikizumab
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Inflammatory Bowel Diseases, Ulcerative Colitis
Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
Ulcerative colitis and Crohn's disease are the commonest types of inflammatory bowel disease (IBD). Both conditions range in severity from no symptoms to being potentially fatal.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT03836612
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 95,055 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Ulcerative Colitis, Crohn's Disease
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
This is a randomized, observer-blinded, placebo-controlled study to evaluate safety, tolerability, immunogenicity, and pharmacokinetics of repeat dosing of intravenous (IV) UTTR1147A.
- Trial name
- NCT02749630
- Testing
- UTTR1147A
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Crohn Disease
Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
The primary objective of this extension study was to obtain long-term safety data for BIRB 796 BS in patients with moderate to severe Crohn's disease after 26 weeks of treatment.
- Trial name
- NCT02209792
- Testing
- BIBR 796 BS, 5 mg, BIBR 796 BS, 20 mg
- Volunteers
- 284 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis, Ankylosing Spondylarthritis
Yuflyma® (Adalimumab), Patient Experience After Switching
Patient preference and experience can impact patients' adherence and persistence regarding a treatment, especially when switching.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- YU-MATTER (NCT05427942)
- Testing
- Adalimumab
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- Celltrion HealthCare France
Healthy Participants
Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants
This is a Phase I, single-centre, open-label, parallel-group, single dose study to evaluate the pharmacokinetics, safety and tolerability of Brazikumab in healthy male and female Chinese participants and healthy male and female…
- Trial name
- NCT05033431
- Testing
- Brazikumab
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Ulcerative Colitis Chronic Moderate
Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO)
The PROCTO trial is a double-blind randomized, placebo-controlled, 24-week, comparative, exploratory phase II proof of concept trial.
- Trial name
- PROCTO (NCT03565939)
- Testing
- Trichuris suis ova
- Where
- Denmark
- Volunteers
- 119 people
- Sponsor
- ParaTech A/S
Ulcerative Colitis
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis
This is a randomized , double-blind, placebo-controlled study of approximately 70 patients with ulcerative colitis.
- Trial name
- NCT00694980
- Testing
- rhuMAb Beta7
- Where
- 30 sites in United States, Belgium and 4 more
- Volunteers
- 48 people
- Sponsor
- Genentech, Inc.
Ulcerative Colitis
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
The purpose of the study is to evaluate the efficacy of cobitolimod treatment compared to placebo in inducing clinical remission, in participants with moderate to severe active left-sided UC and to evaluate the efficacy of…
- Trial name
- CONCLUDE (NCT04985968)
- Testing
- Cobitolimod 250 mg, Cobitolimod 500 mg
- Where
- 203 sites in United States, Australia and 26 more
- Volunteers
- 171 people
- Sponsor
- InDex Pharmaceuticals
COPD, Sepsis
Effect of Nebulized Bronchodilators on Heart Rate
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
- Conditions
- COPD, Sepsis, Shock
- Trial name
- NCT01151579
- Testing
- Levalbuterol, Albuterol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Fahim Khorfan, MD
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Ulcerative Colitis
Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis
The purpose of this study is to investigate whether a novel dosage form of a prednisolone ester, called COLAL-PRED®, is useful in the treatment of ulcerative colitis.
- Trial name
- NCT00299013
- Testing
- COLAL-PRED®, Prednisolone
- Where
- 86 sites in Australia, Belgium and 13 more
- Volunteers
- 796 people
- Sponsor
- Alizyme
Inflammatory Bowel Disease, Ulcerative Colitis
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis
To establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after…
- Trial name
- NCT00408174
- Testing
- Balsalazide disodium
- Where
- 88 sites in United States
- Volunteers
- 400 people
- Sponsor
- Bausch Health Americas, Inc.
Polymyositis, Dermatomyositis
Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or…
- Trial name
- NCT01148810
- Testing
- BAF312
- Where
- 6 sites in United States, Czechia and 3 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Syndrome
Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment
The purpose of the study is to determine whether Viusid administration improves malnutrition, atherosclerosis, erythropoietin response and the frequency of infection episodes in subjects with Chronic Inflammatory Syndrome under…
- Trial name
- NCT00978224
- Testing
- Viusid
- Where
- Cuba
- Volunteers
- 152 people
- Sponsor
- Catalysis SL
Hidradenitis Suppurativa
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis…
- Trial name
- NCT05322473
- Testing
- Sonelokimab (M1095), Adalimumab
- Where
- 57 sites in United States, Bulgaria and 5 more
- Volunteers
- 234 people
- Sponsor
- MoonLake Immunotherapeutics AG
Ulcerative Colitis
FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis
The purpose of this study is to evaluate the safety and efficacy of the drug OPC-6535 compared to a placebo in patients with active Ulcerative Colitis.
- Trial name
- NCT00064454
- Testing
- OPC-6535 Tablets (drug)
- Where
- 28 sites in United States
- Volunteers
- 375 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Septic Shock
Blood Purification for the Treatment of Pathogen Associated Shock
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated…
- Trial name
- PURIFY-RCT (NCT05011656)
- Testing
- Seraph-100 + State of the Art Care, State of the Art Care
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- ExThera Medical Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.